Dr Kumari’s clinical interests lie in taking care of patients with Hepatitis C, cirrhosis and complications, liver cancer and management of post transplant patients. Her research interests are doing Translational research in Portal Hypertension and its complications.
Publications

PUBLICATIONS

- **THE ROLE OF LOCOREGIONAL THERAPY (LRT), POST LRT IMAGING, AND EXPLANT PATHOLOGY AS PREDICTORS OF HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE POST ORTHOTOPIC LIVER TRANSPLANT (OLT)**
  WILEY.2019: 691A–692A

- **Temporal Trends in Disease Presentation and Survival of Patients With Hepatocellular Carcinoma: A Real-World Experience From 1998 to 2015**
  Cancer
  2018; 124 (12): 2588–98

- **Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.**
  Cancer
  2018

- **Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis**
  Nutrients
  Perumpail, B. J., Li, A. A., Cholankeril, G., Kumari, R., Ahmed, A.
  2017; 9 (10)

- **Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma.**
  Journal of clinical gastroenterology
  2017; 51 (4): 384-390

- **Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience.**
  Journal of clinical and translational hepatology
  2017; 5 (1): 23-26

- **Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.**
  Medicine
  2017; 96 (6)

- **Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience**
  JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
  2017; 5 (1): 23–26

- **Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis.**
  Nutrients
  Perumpail, B. J., Li, A. A., Cholankeril, G., Kumari, R., Ahmed, A.
  2017; 9 (10)

- **Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.**
  Alimentary pharmacology & therapeutics
  2016; 44 (7): 738-746

- **Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities**
  WILEY.2016: 860A

- **Outcomes in Patients with Severe Hepatic Encephalopathy and MELD 30 to 34 Justifies Exception to MELD 35 and Higher**
  WILEY.2016: 709A

- **Fulminant Hepatic Failure from Diff use Infiltration by Metastatic Melanoma**
  Holmes, I., Kumari, R.
  NATURE PUBLISHING GROUP.2016: S949–S950
• The Effect of Gastric Acid Suppression on Ledipasivir-Sofosbuvir Effectiveness in Chronic Hepatitis C Infection
  WILEY.2016: 947A

• Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World journal of hepatology
  2015; 7 (29): 2871-2879

• Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis TRANSPLANT INFECTION DISEASE
  2015; 17 (2): 275-278

• Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert opinion on pharmacotherapy
  Kumari, R., Nguyen, M. H.
  2015; 16 (5): 739-748

• Coffee: a panacea or snake oil for the liver? Clinical gastroenterology and hepatology
  Kumari, R., Kim, W. R.
  2014; 12 (9): 1569-1571

• Antibiotic Prophylaxis among Hospitalized End-Stage Liver Disease Patients with Model for End-Stage Liver Disease Score above Thirty: How Do the Physicians in the United States Practice?
  Mathur, A., Puri, N., Kumari, R.
  NATURE PUBLISHING GROUP.2013: S153